农历新年前，中国创新药企业达成的几笔交易，给经历一轮上涨又陷入漫长蛰伏的板块带来暖意。 2026年以来，中国创新药对外授权交易总金额在短短四十多天里已超过300亿美元，首付款规模已超去 年全年单季度最高水平。数字之外，创新药BD（业务拓展）模式的调整，也映射出了中国企业在产业 链中能力与角色的变迁。 即便MNC当前对中国创新药资产的主动性需求更强，且白宫回应称并未"积极考虑"该草案，但BD作为 中国企业当前发展逻辑的关键一环，变幻莫测的地缘政治因素仍然会掣肘中国创新药行业。 图片来源：视觉中国 上周末，信达生物与礼来制药宣布达成新一轮全球战略合作，双方将共同推进肿瘤及免疫领域创新药物 的全球研发。根据协议，信达生物将获得3.5亿美元首付款。在达成后续特定里程碑事件后，信达生物 还有资格获得总额最高约85亿美元的研发、监管及商业化里程碑付款。 这是这家中国创新药公司与礼来的第七次合作。与以往不同的是，本次合作并未围绕公司已有的成熟分 子展开，而是针对尚未成型的新想法，MNC（跨国制药巨头）是为信达生物的早期研发平台和效率付 费，进行"端到端"的全球研发共建。 信达生物将运用其抗体技术平台，主导药物的早期研发，至 ...

全球最新、最好的创新药物，什么时候能来中国？跨国药企赛诺菲正在用实际行动表明，中国可以是全球新药"第一站"。 2025年12月到2026年1月，短短数周内，赛诺菲连续有两款心血管药物在中国获批。它们分别是全球首发的新药阿夫凯泰片（商品名：星舒平 ），有着同类 最佳潜力，以及全球首创的普乐司兰钠注射液（商品名：瑞达普 ），填补了一处重要疾病领域的治疗空白。 实际上，赛诺菲的"心血管双子星"接连获批，也是与中国合作伙伴深度交融的结果，也是赛诺菲创新的BD（business development，业务拓展）模式的明 证。 2025年，堪称中国创新药BD交易爆发元年。医药魔方数据显示，中国创新药BD出海授权2025年交易总金额达到1356.55亿美元，再创历史新高。 在中国创新药纷纷借船出海时，赛诺菲中国则另辟蹊径。2022年底，总部授权赛诺菲中国引进管线的权力。此后，赛诺菲立足中国，主动深入中国本土创新 药生态，发掘最有潜力的药物分子，凭借自身雄厚的开发和商业化实力，让药物最早惠及中国患者。 2024年末以来，赛诺菲分别通过与箕星药业、维亚臻的BD合作，获得了阿夫凯泰片和普乐司兰钠注射液的大中华区开发及商业化权益 ...

Core Viewpoint - BeiGene has entered into an agreement with Royalty Pharma to sell the rights to receive royalties from the global sales of tarlatamab outside of China, with a maximum transaction value of $950 million [1] Group 1: Transaction Details - BeiGene will receive an upfront payment of $885 million and has the option to sell the remaining royalty rights within 12 months for an additional $65 million [1] - The company will also earn a share of revenues from annual sales exceeding $1.5 billion [1] - The transaction does not involve any transfer of intellectual property rights, indicating a new path for business development in innovative drug companies [1][2] Group 2: Market Context and Implications - The deal reflects a growing trend among Chinese innovative drug companies to diversify financing methods beyond traditional equity financing and business development transactions [2] - Tarlatamab is the first approved DLL3-targeted drug globally, and this transaction allows BeiGene to monetize potential future revenues while reducing uncertainty from market competition [2][6] - The collaboration with Royalty Pharma, a leading player in royalty transactions, marks a significant step for BeiGene in the commercialization of its products [3] Group 3: Ongoing Development and Future Prospects - BeiGene continues its collaboration with Amgen on tarlatamab, which has shown positive results in clinical trials for small cell lung cancer (SCLC) [4] - The drug is expected to provide new treatment options for SCLC patients and has been included in treatment recommendations [4] - The company aims to submit applications for related indications within the year, further enhancing its competitive position in the innovative drug market [4] Group 4: Financial Performance - In the first half of 2025, BeiGene reported an operating profit of 799 million yuan and a net profit attributable to shareholders of 450 million yuan, marking a turnaround from losses in the previous year [8] - The company emphasizes the importance of a robust pipeline and self-commercialization capabilities for sustainable growth in the innovative drug sector [7][8]

Core Viewpoint - The launch of the Beijing Stock Exchange (BSE) Specialized and Innovative Index on June 30 marks the beginning of a "dual index" era for the BSE, enhancing its market influence and providing new investment opportunities for investors [1][2]. Group 1: Index Launch and Market Impact - The BSE's total market capitalization has exceeded 800 billion yuan, with specialized and innovative "little giant" enterprises accounting for over half of this value [1][2]. - The new index will include 50 securities selected based on market capitalization and liquidity from the "little giant" enterprises, aiming to objectively reflect their operational status [1][2]. - The introduction of the index is expected to facilitate the development of index ETFs and other investment products, allowing investors to participate more actively in the BSE market [1][2][3]. Group 2: Company Representation and Investment Opportunities - The inclusion of companies in the new index signifies their high market capitalization and representativeness among specialized and innovative enterprises, enhancing their market visibility and brand image [2][3]. - The index is anticipated to guide social resources towards key sectors and strategic emerging industries, promoting innovation and development within these fields [2][3]. - Investors are encouraged to diversify their portfolios based on their risk preferences and investment goals, with the potential for public funds to be developed based on the new index [2][3]. Group 3: Future Outlook and Sector Focus - The BSE's Specialized and Innovative Index reflects its commitment to serving innovative small and medium-sized enterprises, with plans for more industry-specific indices in the future [3]. - Analysts suggest focusing on sectors such as robotics, semiconductor testing, and consumer goods, highlighting specific companies like Suzhou Axle, Audiwei, and Hualing [4].

Group 1 - The U.S. Federal Circuit Court has approved Trump's request to pause the implementation of a previous ruling, allowing him to continue collecting tariffs until the appeal is resolved [1][2][3] - Market sentiment appears to be influenced by this development, with a previous expectation of a complete tariff cancellation being overly optimistic [4][5] - The recent market fluctuations reflect extreme reactions, particularly in the context of short-term trading, with significant losses in previously popular assets [5][6] Group 2 - Trump's recent comments suggest a serious violation of agreements made in Switzerland, although specifics were not provided [8][9] - The timing of Trump's statements was strategic, aimed at generating media attention and market response [12][13] - The approach taken by Trump is seen as a form of extreme pressure to prompt dialogue and concessions from other parties [14] Group 3 - The innovative drug sector has shown strong performance, driven by significant news, including a $6 billion licensing deal between a Hong Kong company and Pfizer [16] - Business Development (BD) is a key strategy for Chinese innovative drugs to enter international markets, with two main models: License-out and New-Co [17][18] - China's innovative drug development has made significant progress, with 3,575 active innovative drugs expected by the end of 2024, surpassing the U.S. [21] - The focus for future innovation should be on creating unique solutions rather than competing in saturated markets, to better serve public health needs [26]